GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Common Stock

TLPPF (Telix Pharmaceuticals) Common Stock : $0.0 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Common Stock?

Telix Pharmaceuticals's quarterly common stock increased from Dec. 2023 ($0.0 Mil) to Jun. 2024 ($390.0 Mil) but then declined from Jun. 2024 ($390.0 Mil) to Dec. 2024 ($0.0 Mil).

Telix Pharmaceuticals's annual common stock declined from Dec. 2022 ($250.3 Mil) to Dec. 2023 ($0.0 Mil) but then stayed the same from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.0 Mil).

Telix Pharmaceuticals Common Stock Historical Data

The historical data trend for Telix Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Common Stock Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 125.80 122.20 250.32 - -

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 250.32 263.02 - 390.05 -

Telix Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Telix Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Common Stock
Comparable Companies
ASX:MSB ASX:NEU ASX:BOT ASX:OPT ASX:CU6 ASX:PYC ASX:CUV ASX:IMM ASX:OCC ASX:IMU VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TLX:USA T3X:Germany TLX:Australia
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Website
https://www.telixpharma.com
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.